Skip to content

Role of homoeopathic medicines in cholelithiasis

Comparative effectiveness of Individualised Homoeopathic Medicine and Chionanthus virginica in cases of Cholelithiasis: An open-label randomised clinical trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097484
Enrollment
40
Registered
2025-11-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K80- Cholelithiasis

Interventions

Intervention1: Individualised homoeopathic medicine: After detailed case taking, Individualised homoeopathic medicine will be prescribed to one arm based on randomisation chart. Dose, potency and repe

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participants between 18-60 years of age, all genders, all regions and races irrespective of socioeconomic status. 2. Participants diagnosed with cholelithiasis in USG Abdomen. 3. Participants who are willing to fill the respective consent forms. 4. Participants who are able to read or understand Hindi, English or Bengali.

Exclusion criteria

Exclusion criteria: 1. Participants with history and/or signs and symptoms of acute Cholecystitis. 2. Participants who need emergency surgical intervention and complications like choledocholithiasis or obstructive jaundice or gall bladder perforation or malignancy or gall stone pancreatitis or perforation or fistula or empyema or gangrene or liver failure or gall stone ileus or cholangitis. 3. Participants harboring gallstones in a congenitally anomalous gallbladder. 4. Participants with markedly deranged LFT parameters such as Serum bilirubin greater than 3mg per dL SGOT greater than 3 times upper limit of normal SGPT greater than 3 times upper limit of normal Serum Albumin greater than 3g per dL 5. Pregnant and lactating women. 6. Participants having any terminal disease conditions. 7. Participants suffering from any psychiatric illness.

Design outcomes

Secondary

MeasureTime frame
Size of gall stone in USG AbdomenTimepoint: At baseline & after 6 months

Primary

MeasureTime frame
Gastrointestinal Quality of Life Index (GIQLI) ScoreTimepoint: At baseline & after 6 months

Countries

India

Contacts

Public ContactProf Dr Prasanta Rath

National Institute of Homoeopathy Kolkata

drprasantarath09@gmail.com8420924836

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026